Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Lee, Kyu-Sun; Noh, Jae Hyung; Park, Seong‐Mi; Choi, Kyung Mook; Kang, Seok Min; Won, Kyu Chang; Cho, Hyun‐Jai; Moon, Min Kyong

doi:10.36628/ijhf.2022.0028

Cited by 6 publications

(2 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the association between the presence of gestational diabetes, which frequently occurs in patients with high BMI, and a worse prognosis, it suggests that metabolic factors may be involved. 29 , 30 , 31 , 32 …”

Section: Discussionmentioning

confidence: 99%

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years

Bak,

Youn,

Bae

et al. 2024

JAHA

View full text Add to dashboard Cite

Background Although peripartum cardiomyopathy (PPCM) is a fatal disease affecting young patients and fetuses, little is known about its recent prognosis and risk factors. This study investigated temporal trends in clinical characteristics and outcomes for PPCM in a nationwide multicenter registry. Methods and Results The study population comprised 340 patients (mean age, 33 years) who were diagnosed with PPCM between January 2000 and September 2022 in 26 tertiary hospitals in South Korea. PPCM was defined as heart failure with left ventricular ejection fraction ≤45% and no previously known cardiac disease. The main study outcomes included time to the first occurrence of all‐cause death, heart transplantation, and cardiovascular hospitalization. The diagnosis of PPCM cases increased notably during the study period ( P <0.001). However, clinical outcomes showed no significant improvement (all‐cause death for 10 years: 0.9% [2000–2010] versus 2.3% [2011–2022], P =0.450; all‐cause death and heart transplantation for 10 years: 3.6% [2000–2010] versus 3.0% [2011–2022] P =0.520; all‐cause death, heart transplantation, and cardiovascular hospitalization for 10 years: 11.7% [2000–2010] versus 19.8% [2011–2022], P =0.240). High body mass index (hazard ratio [HR], 1.106 [95% CI, 1.024–1.196]; P =0.011), the presence of gestational diabetes (HR, 5.346 [95% CI, 1.778–16.07]; P =0.002), and increased baseline left ventricular end‐diastolic dimension (HR, 1.078 [95% CI, 1.002–1.159]; P =0.044) were significant risk factors for poor prognosis. Conclusions While the incidence of PPCM has increased over the past 20 years, the prognosis has not improved significantly. Timely management and close follow‐up are necessary for high‐risk patients with PPCM with high body mass index, gestational diabetes, or large left ventricular end‐diastolic dimension.

show abstract

Section: Discussionmentioning

confidence: 99%

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years

Bak,

Youn,

Bae

et al. 2024

JAHA

View full text Add to dashboard Cite

show abstract

“… 29) The diagnostic algorithm for HF is illustrated in Figure 2 . 2) 30) The diagnostic algorithm for acute HF is illustrated in Figure 3 . 2) …”

Section: Diagnostic Algorithm For Heart Failurementioning

confidence: 99%

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis

Cho

Youn

et al. 2023

Korean Circ J

Self Cite

View full text Add to dashboard Cite

Author's summary The Korean Society of Heart Failure guidelines have been updated based on previously issued international guidelines and research data on Korean patients with heart failure (HF). Herein, Part I of this guideline has discussed the definition, epidemiology, and diagnosis of HF. In particular, the appropriate diagnosis of HF with preserved ejection fraction (HFpEF) has been emphasized given the development of newer therapeutic agents for this condition. Moreover, 2 scoring systems for the diagnosis of HFpEF have been covered in this part of the guidelines. It will provide physicians with up-to-date evidence-based recommendations for the management of patients with HF.

show abstract

Angiotensin receptor‐neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction

Cho,

Choi,

Youn

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsWhether medication adherence to angiotensin receptor‐neprilysin inhibitor (ARNI) in real‐world practice is associated with the reduced risk of all‐cause mortality or hospitalization relative to that with traditional renin–angiotensin system (RAS) blockade remains unclear. This study investigated the influence of medication adherence of ARNI and traditional RAS blockade in heart failure with reduced ejection fraction (HFrEF).MethodWe conducted a nationwide longitudinal cohort study with patients with HFrEF using data from the Korean National Health Insurance Service data (2017–2021) covering the entire population. A total of 13 483 patients with HFrEF who received ARNI were matched 1:1 with 13 483 patients who received traditional RAS blockade using propensity score matching. The primary outcome was a composite of all‐cause mortality or any hospitalization within one year. Medication adherence was assessed by calculating the proportion of days covered (PDC) relative to total medication prescribed. ARNI and traditional RAS blockade adherence rates were directly compared to analyse their respective associations with the primary outcome.ResultsPatients in the ARNI group had a lower rate of the primary outcome than those in the traditional RAS blockade group [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.75–0.81; P < 0.001]. Mean PDC values spanning 1 year were 92.6 ± 14.5% and 90.9 ± 17.7% in the ARNI and RAS blockade groups, respectively (P < 0.001). Among patients with PDC ≥ 80%, the risk of primary outcome was significantly lower in the ARNI group than in the RAS blockade group (HR 0.75; 95% CI 0.72–0.78; P < 0.001) while a risk reduction with ARNI was not observed among patients with PDC < 80% (HR 0.95; 95% CI 0.85–1.05; P = 0.313). The beneficial effect was more pronounced among patients with PDC ≥ 80% than that among patients with PDC < 80% (P for interaction <0.001).ConclusionsIn a real‐world cohort with HFrEF, ARNI was superior to traditional RAS blockade in reducing the risk of all‐cause mortality and hospitalization. The benefit of ARNI was pronounced among patients with high medication adherence but not among those with low medication adherence, highlighting the importance of adherence to ARNI treatment for HFrEF.Trial RegistrationPARADE‐HF ClinicalTrials.gov number, NCT05329727.

show abstract

Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Cited by 6 publications

References 104 publications

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years

Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis

Angiotensin receptor‐neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction

Contact Info

Product

Resources

About